# Oramed Pharmaceuticals Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Oramed Pharmaceuticals Inc). ## Overview Oramed Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company focused on developing oral delivery technologies for drugs that are traditionally administered by injection. Its core work centers on oral insulin and related platform technologies, with development activities conducted through the company and its subsidiaries and joint venture entities. ## Products & services • Oral insulin development and commercialization • Oral drug delivery technology platform • Technology licensing and collaboration agreements • Royalty and profit-sharing interests in partnered products - **Oral insulin programs** (60%) — Development of oral insulin candidates and related clinical and commercialization activities. - **Drug delivery technology licensing** (20%) — Licensing of proprietary oral delivery technology to partners for development use. - **Joint venture development** (10%) — Participation in joint ventures formed to advance oral insulin and related assets. - **Royalty and profit interests** (10%) — Economic interests in partnered products through royalties or profit-sharing arrangements. - Oral insulin development and commercialization - Oral drug delivery technology platform - Technology licensing and collaboration agreements - Royalty and profit-sharing interests in partnered products ## Customers Oramed’s direct counterparties are typically pharmaceutical and biotechnology partners, rather than end patients, because the company monetizes its technology through development collaborations, licenses, and joint ventures. Its commercial value depends on partners that can fund clinical development, manufacture at scale, and help bring oral formulations to market. In addition, the company may ultimately serve patients with diabetes and other chronic conditions through oral alternatives to injectable therapies. - **Pharmaceutical and biotech partners** (primary) — License or co-develop oral drug delivery assets and share development/commercial economics. - **Manufacturing collaborators** (secondary) — Provide formulation and production capabilities needed to scale oral insulin programs. - **Patients with diabetes** (emerging) — End users of oral insulin products if the programs reach commercialization. - Pharmaceutical partners seeking oral delivery technology - Biotech collaborators funding clinical development - Manufacturing partners providing production capacity - Patients with diabetes targeted by oral insulin products ## Geography Oramed is headquartered in the United States, but a substantial part of its technology and development history is tied to Israel through licensing, regulatory, and collaboration activities. The company’s partnerships also point to a broader international footprint, including commercialization rights outside the United States for certain products. Geography matters because clinical development, manufacturing, and licensing rights are split across jurisdictions. - Headquartered in the United States - Technology and development ties to Israel - International commercialization rights through partners - Cross-border regulatory and manufacturing dependencies ## Strategy Oramed’s strategy is centered on advancing oral insulin through partnerships that combine its proprietary technology with external manufacturing and funding. The company also seeks to create value through licensing, royalties, and joint venture structures that can move development risk and capital needs to partners. Its broader portfolio includes investments and contractual interests that may supplement the core oral insulin platform. - **Advance oral insulin development through OraTech** (medium-term) — Combines proprietary technology with partner manufacturing and funding to progress the lead program. - **Monetize technology through partnerships** (short-term) — Licensing and royalty structures can create value without fully funding commercialization internally. - **Maintain financing flexibility** (short-term) — Clinical development and venture formation require ongoing capital support. - Advance oral insulin through a joint venture structure - Use partners for manufacturing and commercialization scale - Monetize technology through licenses and royalty streams - Preserve optionality through investments and contractual interests ## Risks Oramed faces the typical risks of a clinical-stage biotechnology company, including development failure, regulatory delays, and the need for substantial external funding. Its value creation also depends on counterparties honoring joint venture, licensing, and warrant-related obligations, while cross-border trade and policy changes can affect execution. Because the company relies on a small number of programs and partner structures, setbacks in any one arrangement can have an outsized impact. - **Oral insulin development may fail or be delayed** [high] — Clinical-stage drug candidates can fail on efficacy, safety, or trial design. - **Dependence on HTIT and other partners** [high] — The business model relies on counterparties for manufacturing, funding, and commercialization. - **Financing needs may exceed internal resources** [high] — R&D and clinical programs require ongoing capital before product revenue exists. - **Trade policy and tariff changes could affect JV execution** [medium] — Cross-border economic disruption may delay or complicate partner commitments. - **Monetization of warrants and investments is uncertain** [medium] — Value depends on market conditions, contractual performance, and regulatory limits. - Clinical development risk for oral insulin programs - Regulatory approval and trial execution uncertainty - Dependence on partners for funding and manufacturing - Counterparty risk in licenses, royalties, and warrants - Trade policy and macro volatility may disrupt JV execution ## Accounting Oramed’s reported results are affected by revenue recognition on licensing arrangements, including deferred or milestone-like contract economics tied to partner agreements. The company also has judgment-heavy accounting around research and development spending, fair value measurements for investments, and the treatment of obligations or reimbursements linked to government grants and technology transfers. Because the business is development-stage, timing of collaboration revenue and expense recognition can materially change quarterly comparability. - **Revenue recognition on license agreements** — Can create uneven quarterly revenue recognition - **Research and development expense allocation** — Affects operating expense trend and comparability - **Fair value accounting for investments** — Can introduce non-operating gains and losses - **Grant-related obligations and technology transfer costs** — Can materially affect gross margin in the period recognized - License revenue timing can create quarter-to-quarter volatility - R&D spending may be expensed directly or through the JV - Fair value changes on investments can affect reported earnings - Government grant repayment and technology transfer costs matter - Tax provision uses estimated annual effective tax rate --- *Last updated: 2026-09-24T11:13:28.547068+00:00*